The pharmaceutical market: a transdisciplinary description of concepts and their implications
Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 325-338
DOI: 10.1080/14737167.2026.2613683 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 08.01.2026. Verfasst von André Soares Motta-Santos und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Business, University of Southern Queensland (UniSQ), Toowoomba, Australia. Hauptthemen laut MEDLINE: Drug Industry, Drug Costs, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 142 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: The pharmaceutical industry has delivered innovative therapies that substantially improved health outcomes. However, concerns persist regarding high drug prices and delays in the entry of competitors. This article provides a comprehensive and transdisciplinary overview of the pharmaceutical market. References were identified and selected from Medline, Lilacs, Embase, and Google Scholar until thematic saturation. Particular attention is devoted to the market for monoclonal antibodies (mAbs), given their high prices and expanding commercial relevance. AREAS COVERED: The industry is heavily dependent on innovation, with firms investing significant resources in risky R&D and charging high prices for new technologies. Although companies justify elevated prices based on R&D expenditures, additional market dynamics also sustain high pricing. Operating under imperfect competition, pharmaceutical products often exhibit characteristics of merit and credence goods, while practices such as evergreening and reverse payments reinforce market power. Patients' willingness to pay, especially for life-saving treatments, remains high despite limited understanding of expected outcomes due to informational asymmetry. EXPERT OPINION: Drug prices reflect the interaction of market structure, R&D investment, licensing arrangements, and patient behavior. Biopharmaceuticals entail added complexity and cost. Monopolistic or oligopolistic conditions can result in suboptimal pricing and unmet demand, highlighting the need for stronger regulatory oversight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Business, University of Southern Queensland (UniSQ), Toowoomba, Australia.
- Center for Development and Regional Planning (CEDEPLAR), Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
ORCID-Profile: André Soares Motta-Santos, Kenya Valéria Micaela de Souza Noronha, Leonardo Costa Ribeiro, Jeffrey Gow, Khorshed Alam, Mônica Viegas Andrade
Zitieren
APA
Motta-Santos, A. S., Valéria Micaela de Souza Noronha, K., Ribeiro, L. C., Gow, J., Alam, K., & Andrade, M. V. (2026). The pharmaceutical market: a transdisciplinary description of concepts and their implications. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 325-338. https://doi.org/10.1080/14737167.2026.2613683
Vancouver
Motta-Santos AS, Valéria Micaela de Souza Noronha K, Ribeiro LC, Gow J, Alam K, Andrade MV. The pharmaceutical market: a transdisciplinary description of concepts and their implications. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):325-338. doi:10.1080/14737167.2026.2613683
BibTeX
@article{MottaSantos2026,
author = {Motta-Santos, André Soares and Valéria Micaela de Souza Noronha, Kenya and Ribeiro, Leonardo Costa and Gow, Jeffrey and Alam, Khorshed and Andrade, Mônica Viegas},
title = {The pharmaceutical market: a transdisciplinary description of concepts and their implications},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {3},
pages = {325--338},
doi = {10.1080/14737167.2026.2613683}
}
EUVIMED